Evidence map›Paper›PMID 35298832›Full record

ArticleClinical drug investigation2022

Estimation Model for Healthcare Costs and Intensive Care Units Access for Covid-19 Patients and Evaluation of the Effects of Remdesivir in the Portuguese Context: Hypothetical Study.

Matteo Ruggeri, Alessandro Signorini, Silvia Caravaggio, João Rua, Nuno Luís, Sandra Braz, Filipa Aragão

Open access · bronzeAbstract read
In one paragraph

Article in Clinical drug investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 4 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 2 countries.

Matteo RuggeriNational Center for HTA, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161, Rome, Italy. matteo.ruggeri@iss.it.ORCID http://orcid.org/0000-0002-5703-7424
Alessandro SignoriniDepartment of Business Administration, John Cabot University, Rome, Italy.
Silvia CaravaggioSchool of Medicine, St. Camillus International University of Health Sciences (UniCamillus), Via di Sant'Alessandro, 8, 00131, Rome, Italy.
João RuaCentro Hospitalar Universitário de Coimbra, Coimbra, Portugal.
Nuno LuísCentro Hospitalar de Setúbal, Setúbal, Portugal.
Sandra BrazCentro Hospitalar Lisboa Norte, Hospital Santa Maria, Lisbon, Portugal.
Filipa AragãoMaple Health Group, New York, NY, USA.
Centro Hospitalar Lisboa Norte · PTHospitais da Universidade de Coimbra · PTHospital de São Bernardo · PTIstituto Superiore di Sanità · ITJohn Cabot University · ITSaint Camillus International University of Health and Medical Sciences · ITUniversidade Nova de Lisboa · PT

Funding

Gilead Sciences 38,000.00 EUR
6 · The paper itself

Abstract

BACKGROUND AND

objectivesIn March 2020, the World Health Organization announced a state of emergency due to the appearance of a pandemic caused by the Coronavirus 2 (SARS-CoV-2), a severe acute respiratory syndrome, known as Covid-19. Most governments chose to implement precautionary measures, e.g., physical distancing and use of protective devices, which can in part limit the transmission of the virus. However, the healthcare system experienced numerous structural problems in managing the Covid-19 patients given the limited human and technical resources in critical areas, such as the intensive care units (ICUs). Different therapeutic solutions should therefore be assessed, which can potentially minimize the negative impact of the disease on patients, favoring their recovery and optimizing healthcare resources. The objective of this study is to simulate the impact of remdesivir treatment on the pandemic course in the long term.

methodsA forecasting model is designed to estimate how remdesivir would impact the ICU capacity and the healthcare costs from the hospital perspective when managing COVID-19 patients. This model is applied in the Portuguese context with a 20-week projection starting on May 1st and concluding on September 18th, 2021. The data inputs were carefully collected by consulting different sources, such as published global literature, official governmental reports, and available infectious diseases databases, i.e., Our World in Data, Portuguese Ministry of Health, and experts' opinions.

resultsThe model showed that the introduction of remdesivir-based treatment in patients with Covid-19 pneumonia requiring supplemental oxygen therapy generates a significant reduction in both the number of ICU admissions and deaths, which would produce more than €23 million in cost savings and avoid more than 261 ICUs admissions and 166 deaths.

conclusionIt is demonstrated that alternative treatments such as remdesivir can reduce both the health burden for healthcare facilities, optimize their management, and improve patients' clinical conditions. However, the model is centered on Rt values, which cannot be generalized to the entire country; hence, the results of this research should be considered as a "hypothetical study".

Indexed as

COVID-19 Drug TreatmentAdenosine MonophosphateAlanineHealth Care CostsHumansIntensive Care UnitsPortugalSARS-CoV-2Adenosine MonophosphateAlanineremdesivir

Identifiers

PMID35298832
PMCPMC8928238
OpenAlexW4221124145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.